COPD-like airway inflammation during RSV infection of older volunteers: INFLAMMAGE

基于广泛的临床前和临床研究，我们假设RSV疾病代表了一种对感染的调节失调和过度活跃的炎症反应。目前还没有针对呼吸道合胞病毒病的特效治疗方法，识别可用药的炎症途径将具有巨大的潜在临床价值。对自然感染的观察性研究受到采样、时间和获取途径的限制。INFLAMMAGE的目的是在伦敦帝国理工学院利用实验性的人类RSV感染来研究成年志愿者的炎症机制。这将使我们能够调查老年不吸烟者和75岁以下吸烟者中的RSV感染；使用体内和体外技术，我们将尝试定义新的临床终点，并发现预测结果的途径和生物标志物。这将使我们能够从葛兰素史克开发流程中的一系列有希望的药物中进行选择，这些药物可以抑制特定的炎症途径。INFLAMMAGE的下一阶段将使我们能够预测GSK经过验证的新型抗炎药对人类RSV疾病的治疗可能产生的影响，并发现包括COPD在内的慢性呼吸道疾病病毒恶化的新疗法。潜在药物在疾病中的测试将形成INFLAMAGE未来的最后阶段。

Based on extensive preclinical and clinical research we hypothesise that RSV disease represents a dysregulated and over-exuberant inflammatory response to infection. There is currently no specific treatment for RSV disease and identification of 'druggable' inflammatory pathways would be of great potential clinical value. Observational studies of natural infection are constrained by sampling, timing and access. The aim of INFLAMMAGE is to investigate the mechanisms of inflammation in adult volunteers using experimental human RSV infections at Imperial College London. This will enable us to investigate the RSV infection in older adult non-smokers and smokers up to 75 years of age; using in vivo and in vitro techniques, we will attempt to define novel clinical end-points and to discover pathways and biomarkers that predict outcome. This will allow us to select from a range of promising drugs in GSK's development pipeline that inhibit specific inflammatory pathways. This next phase of INFLAMMAGE will enable us to predict the possible impact of treatment with validated novel anti-inflammatory agents from GSK in human RSV disease and to discover new treatments for viral exacerbations of chronic respiratory disease, including COPD. The testing of potential drugs in disease will form the future final phase of INFLAMAGE.